GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biomark Diagnostics Inc (OTCPK:BMKDF) » Definitions » Buyback Yield %

Biomark Diagnostics (Biomark Diagnostics) Buyback Yield %

: 0.00 (As of Today)
View and export this data going back to 2015. Start your Free Trial

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Biomark Diagnostics's current buyback yield was 0.00%.


Biomark Diagnostics Buyback Yield % Historical Data

The historical data trend for Biomark Diagnostics's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomark Diagnostics Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Buyback Yield %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.38 -5.40 - - -3.72

Biomark Diagnostics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Buyback Yield % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison

For the Diagnostics & Research subindustry, Biomark Diagnostics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomark Diagnostics Buyback Yield % Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Biomark Diagnostics's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Biomark Diagnostics's Buyback Yield % falls into.



Biomark Diagnostics Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Biomark Diagnostics's Buyback Yield for the fiscal year that ended in Mar. 2023 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 0.441) / 11.8682835
=-3.72%

Biomark Diagnostics's annualized Buyback Yield for the quarter that ended in Dec. 2023 is calculated as

Buyback Yield=Net Issuance of Stock(Annualized) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) * Annualized Factor / Market Cap
=- (0 + 0) * 4 / 16.359516
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the annualized quarterly data, the Repurchase of Stock and Issuance of Stock data used here is four times the quarterly (Dec. 2023) data.


Biomark Diagnostics Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Biomark Diagnostics's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomark Diagnostics (Biomark Diagnostics) Business Description

Traded in Other Exchanges
Address
130 - 3851 Shell Road, Richmond, BC, CAN, V6X 2W2
Biomark Diagnostics Inc is a Canada-based oncology-focused company. It is engaged in the development of the early-stage cancer diagnostic technology platform. The company develops non-invasive cancer diagnostic solutions which will help to detect, monitor, and assess early treatment for cancer. Its research and development are focused on the role that metabolomics plays in early cancer detection. It is currently focused on bringing its liquid biopsy-based cancer diagnostic tests and detection solution to commercialization.

Biomark Diagnostics (Biomark Diagnostics) Headlines

No Headlines